Social Determinants of Health and Other Predictors in Initiation of Treatment with CDK4/6 Inhibitors for HR+/HER2− Metastatic Breast Cancer
Open Access
Abstract
In hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer (MBC), cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) have replaced endocrine therapy alone as the standard of care; however, several barriers to treatment initiation still exist. We assessed social determinants of health (SDOH) and other factors associated with the initiation of CDK4/6i for HR+/HER2− MBC in the Medicare population. Using a retrospective cohort design, patients aged ≥65 years and diagnosed during 2015–2017 were selected from the SEER-Medicare database. Time from MBC diagnosis to first CDK4/6i initiation was the study outcome. The effect of SDOH measures and other predictors on the outcome was assessed using the multivariable Fine and Gray hazard modeling. Of 752 eligible women, 352 (46.8%) initiated CDK4/6i after MBC diagnosis (median time to initiation: 27.9 months). In adjusted analysis, SDOH factors significantly associated with CDK4/6i initiation included high versus low median household income (HHI) (hazard ratio [HR] = 1.70; 95% CI = 1.03–2.81) and the percentage of population with high versus low Medicare-only coverage (HR = 1.54; 95% CI = 1.04–2.27). In summary, older Medicare patients with HR+/HER2− MBC residing in areas with high median HHI and a high proportion of Medicare-only coverage had higher rates of initiating CDK4/6i, suggesting inequitable access to these novel, effective treatments and a need for policy intervention.Keywords
Funding Information
- University of Houston, College of Pharmacy
This publication has 34 references indexed in Scilit:
- Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2– metastatic breast cancer in the United States: A SEER‐Medicare population‐based studyCancer, 2023
- Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2– metastatic breast cancer in the United StatesBreast Cancer Research and Treatment, 2023
- Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancerThe Breast, 2021
- New Studies Reveal Potential Mechanisms of Resistance to CDK4/6 Inhibitors in HR+/HER2– Breast CancerThe Oncologist, 2021
- Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical TrialsJAMA Oncology, 2018
- Practical recommendations for reportingFine‐Gray model analyses for competing risk dataStatistics in Medicine, 2017
- Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancerLung Cancer, 2014
- A Refined Comorbidity Measurement Algorithm for Claims-Based Studies of Breast, Prostate, Colorectal, and Lung Cancer PatientsAnnals of Epidemiology, 2007
- Parity and disparity in first course treatment of invasive breast cancerBreast Cancer Research and Treatment, 2007
- Differences in the quality of breast cancer care among vulnerable populationsCancer, 2005